TRUST is a bust: Bayer ends factor VIIa trial
This article was originally published in Scrip
Executive Summary
Bayer HealthCare discontinued the Phase II/III TRUST clinical trial for its recombinant factor VIIa protein BAY86-6150 after a neutralizing antibody was detected during the course of the trial.